Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review of Antiviral Therapy for Herpes Labialis

A Review of Antiviral Therapy for Herpes Labialis EDITORIAL REVIEW Melody Vander Straten, MD; Daniel Carrasco, MD; Patricia Lee, MD; Stephen K. Tyring, MD, PhD he study by McKeough and Spruance in this issue of the ARCHIVES demonstrates the relative efficacy of 4 topical antiviral agents for the treatment of herpes simplex virus type 1 (HSV-1) infection using the backs of guinea pigs. Efficacy was measured by re- T ductions in lesion number, area, and virus titer. They found, in this model, that the relative efficacy of penciclovir cream was greater than acyclovir cream, acyclovir cream was greater than or equal to acyclovir ointment, and acyclovir ointment was greater than n-docosanol cream. A clinical study comparing all 4 agents would be very expensive and is unlikely ever to be done. The authors note, however, that the guinea pig model is twice as sensitive to antiviral therapies as is herpes labialis. It is therefore interesting that the relative efficacies in the animal model closely reflect the perception of many physicians regarding the efficacy of these agents in herpes labialis. Compared with its vehicle, penciclovir appears to have the greatest clinical benefit for herpes la- bialis. Because HSV-1 infection is primarily neural and not cutaneous, it is logical that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

A Review of Antiviral Therapy for Herpes Labialis

Loading next page...
 
/lp/american-medical-association/a-review-of-antiviral-therapy-for-herpes-labialis-ijlhtgtLtg
Publisher
American Medical Association
Copyright
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.137.9.1232
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL REVIEW Melody Vander Straten, MD; Daniel Carrasco, MD; Patricia Lee, MD; Stephen K. Tyring, MD, PhD he study by McKeough and Spruance in this issue of the ARCHIVES demonstrates the relative efficacy of 4 topical antiviral agents for the treatment of herpes simplex virus type 1 (HSV-1) infection using the backs of guinea pigs. Efficacy was measured by re- T ductions in lesion number, area, and virus titer. They found, in this model, that the relative efficacy of penciclovir cream was greater than acyclovir cream, acyclovir cream was greater than or equal to acyclovir ointment, and acyclovir ointment was greater than n-docosanol cream. A clinical study comparing all 4 agents would be very expensive and is unlikely ever to be done. The authors note, however, that the guinea pig model is twice as sensitive to antiviral therapies as is herpes labialis. It is therefore interesting that the relative efficacies in the animal model closely reflect the perception of many physicians regarding the efficacy of these agents in herpes labialis. Compared with its vehicle, penciclovir appears to have the greatest clinical benefit for herpes la- bialis. Because HSV-1 infection is primarily neural and not cutaneous, it is logical that

Journal

JAMA DermatologyAmerican Medical Association

Published: Sep 1, 2001

References